Clinical trial
HSCT for High Risk Inherited Inborn Errors
NCT00383448 · Masonic Cancer Center, University of Minnesota, Other · Completed
Key facts
| NCT number | NCT00383448 |
|---|---|
| Title | HSCT for High Risk Inherited Inborn Errors |
| Official title | Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis |
| Intervention type | Biological, Device, Drug, Procedure |
| Interventions | Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea |
| Enrollment | 38 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2014 |
| Completion | Sep 1, 2014 |
| First posted | Oct 3, 2006 |
| Last update posted | Jul 11, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: